Loading...
•
Mar 31
Insulet Q1 2025 Earnings Report
Insulet reported strong financial results for the first quarter of 2025, including a 29% increase in revenue year-over-year and improved gross margin and operating income.
Key Takeaways
Insulet delivered a strong first quarter in 2025, exceeding expectations with significant revenue growth driven by the Omnipod platform. The company also saw improvements in profitability metrics and raised its full-year guidance.
Total revenue for Q1 2025 was $569.0 million, a 28.8% increase year-over-year.
Total Omnipod revenue grew by 28.0% to $554.1 million.
Gross margin improved by 240 basis points to 71.9%.
Operating income was $88.8 million, or 15.6% of revenue.
Insulet
Insulet
Insulet Revenue by Segment
Revenue by Segment
U.S. Omnipod Revenue
CapyFin.comInternational Omnipod Revenue
CapyFin.comDrug Delivery Revenue
CapyFin.com Forward Guidance
Insulet raised its full-year revenue and gross margin guidance based on strong first-quarter performance and continued momentum.
Positive Outlook
- Raising full year revenue growth guidance to 19% - 22% (constant currency).
- Raising full year gross margin guidance to approximately 71%.
- Expecting Q2 2025 revenue growth of 23% - 26% (constant currency).
- U.S. Omnipod full-year guidance increased to 18% - 21% growth.
- International Omnipod full-year guidance increased to 27% - 30% growth.
Challenges Ahead
- Drug Delivery revenue expected to decrease by 35% - 25% for the full year.
- Constant currency impact expected to be 1% for total revenue for the full year.
- Constant currency impact expected to be 2% for International Omnipod for the full year.
- Constant currency impact expected to be 5% for International Omnipod for Q2 2025.
- Constant currency impact expected to be 1% for total revenue for Q2 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income